Ilio Vitale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5228317/publications.pdf

Version: 2024-02-01

131 papers	24,236 citations	31976 53 h-index	16650 123 g-index
131 all docs	131 docs citations	131 times ranked	35739 citing authors

#	Article	IF	Citations
1	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
2	Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and Differentiation, 2012, 19, 107-120.	11.2	2,144
3	Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.	5.9	2,058
4	Regulation of autophagy by cytoplasmic p53. Nature Cell Biology, 2008, 10, 676-687.	10.3	1,025
5	Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 2019, 30, 36-50.	16.2	933
6	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	30.7	823
7	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	11.2	811
8	Cell death modalities: classification and pathophysiological implications. Cell Death and Differentiation, 2007, 14, 1237-1243.	11.2	688
9	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
10	Mitotic catastrophe: a mechanism for avoiding genomic instability. Nature Reviews Molecular Cell Biology, 2011, 12, 385-392.	37.0	682
11	Systems biology of cisplatin resistance: past, present and future. Cell Death and Disease, 2014, 5, e1257-e1257.	6.3	625
12	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
13	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death and Differentiation, 2009, 16, 1093-1107.	11.2	599
14	Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death and Disease, 2010, 1, e10-e10.	6.3	518
15	Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 2021, 27, 212-224.	30.7	376
16	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	12.6	367
17	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	12.6	367
18	The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death and Differentiation, 2008, 15, 1499-1509.	11.2	298

#	Article	IF	Citations
19	Regulation of autophagy by the inositol trisphosphate receptor. Cell Death and Differentiation, 2007, 14, 1029-1039.	11.2	285
20	The IKK complex contributes to the induction of autophagy. EMBO Journal, 2010, 29, 619-631.	7.8	274
21	miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death. Cancer Research, 2010, 70, 1793-1803.	0.9	262
22	DNA Damage in Stem Cells. Molecular Cell, 2017, 66, 306-319.	9.7	259
23	The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death and Differentiation, 2009, 16, 1006-1017.	11.2	258
24	Mitochondrial gateways to cancer. Molecular Aspects of Medicine, 2010, 31, 1-20.	6.4	239
25	Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nature Immunology, 2020, 21, 120-134.	14.5	218
26	Apoptosis regulation in tetraploid cancer cells. EMBO Journal, 2006, 25, 2584-2595.	7.8	180
27	Autophagic removal of micronuclei. Cell Cycle, 2012, 11, 170-176.	2.6	162
28	Methods for Assessing Autophagy and Autophagic Cell Death. Methods in Molecular Biology, 2008, 445, 29-76.	0.9	159
29	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO Journal, 2010, 29, 1272-1284.	7.8	155
30	Chloroquine and hydroxychloroquine for cancer therapy. Molecular and Cellular Oncology, 2014, 1, e29911.	0.7	154
31	Calcium signaling and cell cycle: Progression or death. Cell Calcium, 2018, 70, 3-15.	2.4	152
32	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150
33	Cisplatin Resistance Associated with PARP Hyperactivation. Cancer Research, 2013, 73, 2271-2280.	0.9	143
34	The life span-prolonging effect of Sirtuin-1 is mediated by autophagy. Autophagy, 2010, 6, 186-188.	9.1	127
35	Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death and Differentiation, 2011, 18, 1403-1413.	11.2	125
36	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122

#	Article	IF	Citations
37	Cell Cycle-Dependent Induction of Autophagy, Mitophagy and Reticulophagy. Cell Cycle, 2007, 6, 2263-2267.	2.6	117
38	Trial Watch: Targeting ATMâ€“CHK2 and ATRâ€“CHK1 pathways for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e1012976.	0.7	117
39	Oncogene-induced senescence and tumour control in complex biological systems. Cell Death and Differentiation, 2018, 25, 1005-1006.	11.2	110
40	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene, 2013, 32, 4995-5004.	5.9	108
41	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. OncoImmunology, 2017, 6, e1314424.	4.6	106
42	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. Cancer Research, 2008, 68, 5301-5308.	0.9	101
43	Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 2014, 33, 3894-3907.	5.9	89
44	Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death and Differentiation, 2013, 20, 1532-1545.	11.2	88
45	Oncosuppressive Functions of Autophagy. Antioxidants and Redox Signaling, 2011, 14, 2251-2269.	5.4	86
46	Trial Watch. OncoImmunology, 2013, 2, e25595.	4.6	83
47	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Reviews in Molecular Medicine, 2015, 17, e14.	3.9	75
48	Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE, 2007, 2, e1337.	2.5	67
49	Mitochondrial Liaisons of p53. Antioxidants and Redox Signaling, 2011, 15, 1691-1714.	5.4	66
50	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	7.9	66
51	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 2018, 67, 903-917.	12.1	64
52	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. Frontiers in Immunology, 2020, 11, 2166.	4.8	60
53	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3020-3025.	7.1	59
54	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle, 2013, 12, 877-883.	2.6	57

#	Article	IF	Citations
55	MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology, 2014, 92, 55-61.	4.4	54
56	Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene, 2009, 28, 4249-4260.	5.9	53
57	Viral strategies for the evasion of immunogenic cell death. Journal of Internal Medicine, 2010, 267, 526-542.	6.0	53
58	Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 155-166.	4.9	51
59	Selective Resistance of Tetraploid Cancer Cells against DNA Damage-Induced Apoptosis. Annals of the New York Academy of Sciences, 2006, 1090, 35-49.	3.8	50
60	Selective killing of p53â€deficient cancer cells by SP600125. EMBO Molecular Medicine, 2012, 4, 500-514.	6.9	47
61	IKK connects autophagy to major stress pathways. Autophagy, 2010, 6, 189-191.	9.1	46
62	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	2.8	46
63	The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 659-669.	4.9	41
64	Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle, 2008, 7, 1956-1961.	2.6	41
65	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Cell Cycle, 2009, 8, 1030-1035.	2.6	40
66	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	4.6	40
67	ATM kinase sustains breast cancer stem-like cells by promoting ATG4C expression and autophagy. Oncotarget, 2017, 8, 21692-21709.	1.8	39
68	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. Cell Cycle, 2009, 8, 1380-1385.	2.6	38
69	Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle, 2009, 8, 3971-3977.	2.6	38
70	Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases. International Review of Cell and Molecular Biology, 2017, 328, 105-161.	3.2	38
71	An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe. Cell Death and Disease, 2010, 1, e25-e25.	6.3	37
72	A fluorescence-microscopic and cytofluorometric system for monitoring the turnover of the autophagic substrate p62/SQSTM1. Autophagy, 2011, 7, 883-891.	9.1	36

#	Article	IF	Citations
73	Immunosurveillance against tetraploidization-induced colon tumorigenesis. Cell Cycle, 2013, 12, 473-479.	2.6	36
74	Role of autophagy in the maintenance and function of cancer stem cells. International Journal of Developmental Biology, 2015, 59, 95-108.	0.6	35
75	Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle, 2012, 11, 2149-2158.	2.6	34
76	Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle, 2012, 11, 3472-3480.	2.6	32
77	A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 182-190.	4.9	31
78	Replication stress response in cancer stem cells as a target for chemotherapy. Seminars in Cancer Biology, 2018, 53, 31-41.	9.6	31
79	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. Oncotarget, 2016, 7, 885-901.	1.8	31
80	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. OncoImmunology, 2016, 5, e1160187.	4.6	30
81	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. International Journal of Cancer, 2017, 140, 2587-2595.	5.1	30
82	Depletion of Endonuclease G Selectively Kills Polyploid Cells. Cell Cycle, 2007, 6, 1072-1076.	2.6	29
83	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends in Cancer, 2015, 1, 124-135.	7.4	28
84	Chapter Eighteen Methods to Dissect Mitochondrial Membrane Permeabilization in the Course of Apoptosis. Methods in Enzymology, 2008, 442, 355-374.	1.0	27
85	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. OncoImmunology, 2015, 4, e988042.	4.6	27
86	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle, 2013, 12, 417-421.	2.6	26
87	PARP and other prospective targets for poisoning cancer cell metabolism. Biochemical Pharmacology, 2014, 92, 164-171.	4.4	24
88	Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells. Molecular and Cellular Oncology, 2017, 4, e1299274.	0.7	24
89	Stress responses in stromal cells and tumor homeostasis. , 2019, 200, 55-68.		22
90	Impact of the Ku Complex on HIV-1 Expression and Latency. PLoS ONE, 2013, 8, e69691.	2.5	22

#	Article	IF	Citations
91	Past, Present, and Future of Molecular and Cellular Oncology. Frontiers in Oncology, 2011, 1, 1.	2.8	20
92	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. OncoImmunology, 2013, 2, e22409.	4.6	20
93	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Annals of Oncology, 2015, 26, 2470-2477.	1.2	20
94	Trial watch â€“ inhibiting PARP enzymes for anticancer therapy. Molecular and Cellular Oncology, 2016, 3, e1053594.	0.7	19
95	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 2021, 28, 2060-2082.	11.2	19
96	Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular and Cellular Oncology, 2015, 2, e974463.	0.7	18
97	Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells. Cell Cycle, 2010, 9, 377-383.	2.6	17
98	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	2.6	16
99	Evaluation of Rapamycin-Induced Cell Death. Methods in Molecular Biology, 2012, 821, 125-169.	0.9	15
100	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	3.3	14
101	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget, 2015, 6, 42773-42780.	1.8	14
102	Caspase-independent apoptosis is activated by diazepam-induced mitotic failure in HeLa cells, but not in human primary fibroblasts. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 909-920.	4.9	12
103	Body mass index modifies the relationship between Î³-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer, 2017, 17, 101.	2.6	12
104	The clinical significance of PD-L1 in advanced gastric cancer is dependent onARID1Amutations and ATM expression. OncoImmunology, 2018, 7, e1457602.	4.6	11
105	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. PLoS ONE, 2016, 11, e0149872.	2.5	11
106	Cytofluorometric Assessment of Cell Cycle Progression. Methods in Molecular Biology, 2013, 965, 93-120.	0.9	10
107	BRIO: a web server for RNA sequence and structure motif scan. Nucleic Acids Research, 2021, 49, W67-W71.	14.5	10
108	Immunosurveillance against cancer-associated hyperploidy. Oncotarget, 2012, 3, 1270-1271.	1.8	10

#	Article	IF	Citations
109	Involvement of p38Î± in the mitotic progression ofp53^{-/-}tetraploid cells. Cell Cycle, 2010, 9, 2895-2901.	2.6	8
110	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. Cancers, 2021, 13, 1957.	3.7	8
111	Using epigenetic modifiers to target cancer stem cell immunoevasion. Cancer Cell, 2021, 39, 1573-1575.	16.8	7
112	Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle, 2012, 11, 3157-3158.	2.6	6
113	A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis. Oncogene, 2010, 29, 5869-5872.	5.9	5
114	Transgenerational cell fate profiling. Cell Cycle, 2013, 12, 183-190.	2.6	5
115	Driving to Cancer on a Four-Lane Expressway. Trends in Genetics, 2017, 33, 491-492.	6.7	5
116	Cytofluorometric Purification of Diploid and Tetraploid Cancer Cells. Methods in Molecular Biology, 2011, 761, 47-63.	0.9	5
117	Catastrophic DNA replication in unscheduled tetraploid cells. Trends in Genetics, 2022, 38, 787-788.	6.7	5
118	Spontaneous DNA damage propels tumorigenicity. Cell Research, 2017, 27, 720-721.	12.0	4
119	LTX-315, CAPtivating immunity with necrosis. Cell Cycle, 2016, 15, 1176-1177.	2.6	3
120	Everybody In! No Bouncers at Tumor Gates. Trends in Genetics, 2018, 34, 85-87.	6.7	3
121	Relative Information Gain: Shannon entropy-based measure of the relative structural conservation in RNA alignments. NAR Genomics and Bioinformatics, 2021, 3, lqab007.	3.2	3
122	Synchronization and Desynchronization of Cells by Interventions on the Spindle Assembly Checkpoint. Methods in Molecular Biology, 2017, 1524, 77-95.	0.9	2
123	Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. Methods in Molecular Biology, 2016, 1417, 231-245.	0.9	1
124	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. Methods in Enzymology, 2020, 632, 39-54.	1.0	1
125	Replication stress in colorectal cancer stem cells. Oncotarget, 2017, 8, 90606-90607.	1.8	1
126	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	6.4	0

#	Article	IF	Citations
127	Signal Transduction Networks Analysis: The Reverse Phase Protein Array. , 2017, , .		0
128	Molecular Mechanisms of Immunogenic Cell Death. , 2017, , .		0
129	Caspase 2 and p53 Reunited in Tumor Control. Trends in Cell Biology, 2020, 30, 917-918.	7.9	0
130	Oncosuppressive functions of PIDD1 in response to centrosome amplification. Cell Death and Disease, 2021, 12, 175.	6.3	0
131	Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors. , 2012, , .		0